Biogen Reports Two-Year Diranersen Data in Early Alzheimer’s Disease
Biogen said Phase 2 CELIA study data show increasing clinical benefit from investigational diranersen in people with early Alzheimer’s disease.
Biogen said Phase 2 CELIA study data show increasing clinical benefit from investigational diranersen in people with early Alzheimer’s disease.